CEL-SCI (FRA:LSR) Other Current Liabilities: €0.00 Mil (As of Mar. 2026)


FRA:LSR CEL-SCI Corp FRA:LSR
23 GF Score
Price €0.82
! 2 Warning Signs
View Full Analysis

What is CEL-SCI Other Current Liabilities?

CEL-SCI FRA:LSR -4.12% 23 Other Current Liabilities is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:LSR with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

CEL-SCI's other current liabilities for the quarter that ended in Mar. 2026 was €0.00 Mil.

CEL-SCI's quarterly other current liabilities increased from Sep. 2025 (€0.00 Mil) to Dec. 2025 (€0.00 Mil) but then declined from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€0.00 Mil).

CEL-SCI Other Current Liabilities Related Terms

CEL-SCI Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for CEL-SCI's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEL-SCI Other Current Liabilities Chart

CEL-SCI Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.00 0.00 0.00 0.00

CEL-SCI Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00
FRA:LSR
23GF Score
CEL-SCI Corp FRA:LSR
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CEL-SCI Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €0.00 Mil mean?
CEL-SCI (FRA:LSR) has a Other Current Liabilities of €0.00 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on CEL-SCI.
Is CEL-SCI's Other Current Liabilities too high?
CEL-SCI's current Other Current Liabilities is €0.00 Mil. Overall, CEL-SCI has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does CEL-SCI's Other Current Liabilities compare to OTLC and AEON?
CEL-SCI's Other Current Liabilities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on CEL-SCI. CEL-SCI's current Other Current Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CEL-SCI stock overvalued right now?
CEL-SCI (FRA:LSR) has a current Other Current Liabilities of €0.00 Mil. The current Other Current Liabilities is €0.00 Mil. CEL-SCI's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For CEL-SCI (FRA:LSR), the current Other Current Liabilities is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CEL-SCI Business Description

Other Exchanges CVM:USA
Address 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
23GF Score

Get the complete analysis for FRA:LSR

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.82
Price